Screener
CRISPR Therapeutics CRSP Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| General and administrative | 17,183 | 19,296 |
| Collaboration expense, net | 45,949 | 57,509 |
| Total operating expenses | 131,706 | 149,289 |
| Loss from operations | (130,248) | (148,424) |
| Other income: | ||
| Other income, net | 8,156 | 13,537 |
| Total other income, net | 8,156 | 13,537 |
| Net loss before income taxes | (122,092) | (134,887) |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's operating income?
- CRISPR Therapeutics (CRSP) reported operating income of -$130.25M in Q1 2026.
- How has CRISPR Therapeutics's operating income changed year-over-year?
- CRISPR Therapeutics's operating income increased by 12.2% year-over-year, from -$148.42M to -$130.25M.
- What is the long-term trend for CRISPR Therapeutics's operating income?
- Over 2 years (2022 to 2025), CRISPR Therapeutics's operating income has grown at a -0.6% compound annual growth rate (CAGR), from -$673.16M to -$664.57M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about CRISPR Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude